The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 06, 2022
Filed:
Aug. 07, 2017
Applicant:
Glycomimetics, Inc., Rockville, MD (US);
Inventors:
John L. Magnani, Gaithersburg, MD (US);
William E. Fogler, Baltimore, MD (US);
Assignee:
GlycoMimetics, Inc., Rockville, MD (US);
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/7034 (2006.01); C07K 16/28 (2006.01); A61K 47/61 (2017.01); A61P 35/00 (2006.01); A61K 31/197 (2006.01); A61K 31/395 (2006.01); A61K 31/69 (2006.01); A61K 31/702 (2006.01); A61K 31/7068 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7034 (2013.01); A61K 31/197 (2013.01); A61K 31/395 (2013.01); A61K 31/69 (2013.01); A61K 31/702 (2013.01); A61K 31/7068 (2013.01); A61K 39/3955 (2013.01); A61K 47/61 (2017.08); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/76 (2013.01);
Abstract
Compositions and methods for the treatment of diseases, disorders, and/or conditions associated with the increased regulatory T lymphocyte cell function, comprising the administration of T-cell checkpoint inhibitors in combination with E-selectin inhibitors, C—X—C Motif Chemokine Receptor 4 (CXCR4) receptor inhibitors, and/or heterobifunctional inhibitors that comprise at least one E-selectin inhibitor linked to at least one CXCR4 receptor inhibitor, are disclosed.